Prognostic significance of PD-L1 and PD-L2 in breast cancer
Prognostic significance of PD-L1 and PD-L2 in breast cancer
复制标题
DOI：
10.1016/j.humpath.2015.09.006
复制
发表时间：
2016-01-01
期刊：
影响因子：
3.3
通讯作者：
Vassal, Jose
中科院分区：
文献类型：
--
作者：
Baptista, Mauricio Z.;Sarian, Luis Otavio;Vassal, Jose
PD-L1和PD-L2构成重要的抗肿瘤免疫应答。在乳腺癌中，它们的预后价值仍有待确定。在这项研究中，我们研究了PD-L1和PD-L2蛋白表达与临床和病理特征以及无病生存期和总生存期之间的相关性。为了评估PD-L1和PD-L2的表达，我们使用乳腺癌组织微阵列进行了免疫组织化学研究，共包括192例乳腺癌病例，I期，II期和III期，并提供了详细的临床和结局数据。56.6%（107/189）的乳腺癌病例中存在PD-L1表达，50.8%（97/191）的乳腺癌病例中发现PD-L2表达。诊断时年龄较小、淋巴结阳性、雌激素受体阴性和远处复发均与PD-L1和PD-L2表达相关。较大肿瘤的存在仅与PD-L1表达相关。在我们的研究中，PD-L1表达与乳腺癌患者的总生存率显著相关（P = 0.04）。尽管PD-L1表达与不良临床和病理特征相关，但它仍是乳腺癌的一种阳性预后生物标志物。这种存活结果可能是由于存在导致PD-L1表达的强抗肿瘤免疫应答。(C)2015 Elsevier Inc. All rights reserved.
PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression. (C) 2015 Elsevier Inc. All rights reserved.